Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
29 May 2020

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Sun Pharmaceuticals Industries Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 464.85
Net Changes 5.75
Volume 5441373
Prev Close 459.10
464.85 5.75 (1.25%)
Date: May 29,2020 12:19:59




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 459.5 Div Yield (%) 0.87
Buy (Size) 464.80(×6) Eps(Rs) 13.38
Sell (Size) 465.00(×146) Book Value (Stand.)(Rs) 101.68
Value 7757792900 Book Value(conso.)(Rs) 188.6541649
Buy Quantity 6 Market Cap(Rs.Cr) 110189.46
Sell Quantity 146 Face Value(Rs) 1
Today's High 468.85 Market Lot 1
Today's Low 458.75 AGM Date Aug
52-Week High 504.85 Book Closure Date Aug
52-Week Low 315.2 ISIN No. INE044A01036

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 1312134535 54.69
Total of Promoter 1312134535 54.69
Non Promoter (Institution) 776661677 32.37
Non Promoter (Non-Institution) 310538758 12.94
Total Non Promoter 1087200435 45.31
Total Promoter & Non Promoter 2399334970 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 2399334970 100.00

Company News

28-May-2020  SPARC and Sun Pharma enter into licensing agreement for a pote...
SPARC and Sun Pharma enter into licensing agreement for a potential dermatology product

Sun Pharma Advanced Research Company and Sun Pharmaceutical Industries announced a worldwide licensing agreement on the development and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of US$ 20 million. SPARC will also be eligible to receive up to US$ 125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.

27-May-2020  Sun Pharmaceuticals Industries consolidated net profit decline...
Sun Pharmaceuticals Industries consolidated net profit declines 37.12% in the March 2020 quarter

Net profit of Sun Pharmaceuticals Industries declined 37.12% to Rs 399.84 crore in the quarter ended March 2020 as against Rs 635.88 crore during the previous quarter ended March 2019. Sales rose 14.68% to Rs 8078.03 crore in the quarter ended March 2020 as against Rs 7044.26 crore during the previous quarter ended March 2019.

For the full year,net profit rose 41.25% to Rs 3764.93 crore in the year ended March 2020 as against Rs 2665.42 crore during the previous year ended March 2019. Sales rose 12.69% to Rs 32325.17 crore in the year ended March 2020 as against Rs 28686.28 crore during the previous year ended March 2019.

ParticularsQuarter EndedYear Ended
 Mar. 2020Mar. 2019% Var.Mar. 2020Mar. 2019% Var.
Sales8078.037044.26 15 32325.1728686.28 13
OPM %16.8714.43 -21.6221.99 -
PBDT1413.461148.29 23 7323.016777.83 8
PBT838.08694.24 21 5270.235024.58 5
NP399.84635.88 -37 3764.932665.42 41
27-May-2020  Sun Pharma Q4 PAT declines 37% to 399 cr
Sun Pharma Q4 PAT declines 37% to 399 cr

The company recorded a one-time expenditure of Rs 260.64 crore as an exceptional item in the March 2020 quarter. Of the total amount, the charge of Rs 104.28 crore was due to the Supreme Court of India's judgment in a case pertaining to central excise refund claims and Rs 156.36 crore was on account of a settlement made by Dusa Pharmaceuticals, the company's US-based subsidiary, with the U.S. Department of Justice and an individual to resolve allegations relating to the sales, marketing and promotion of two of its products.

Profit before tax (PBT) stood at Rs 577.44 crore in Q4 FY20, down by 16.8% from Rs 694.24 crore in Q4 FY19. Tax expenses in the fourth quarter stood at Rs 83.09 crore. The company had written back taxes to the tune of Rs 28.81 crore in the corresponding period last year.

EBITDA stood at Rs 1,256 crore, with resulting EBITDA margin of 15.5%. Approximately 50% of the EBITDA margin decline versus Q3 FY20 is due to the adverse impact of forex loss in Q4 FY20.

In the fourth quarter, the drug maker's India formulations earnings stood at Rs 2,364.80 (up 114.7% YoY) while US formulations earnings were at Rs 2,712.88 (down 13.2% YoY). Emerging markets' sales came in at Rs 1,353.97 (up 11% YoY) and formulation sales in Rest of World (ROW) markets were at Rs 1,121.22 crore (up 4% YoY). The term 'YoY' indicates year-on-year comparison.

For Q4 FY20, external sales of active pharmaceutical ingredients (API) were at Rs 483.43 crore, flat over Q4 last year. Consolidated R&D investment fell 5.6% to Rs 536 crores in Q4 FY20, from Rs. 567.49 crores reported in Q4 last year.

Consolidated net profit jumped 41.3% to Rs 3,764.93 crore on a 13% rise in total revenue from operations to Rs 32,837.50 crore in the year ended March 2020 (FY20) over the year ended March 2019 (FY19). PBT stood at Rs 5,009.59 crore in FY20, up by 31.5% from Rs 3,810.20 crore in FY19.

Dilip Shanghvi, managing director of the company said, 'I am happy to see that we are able to maintain business continuity in these challenging times, so that patients continue to get access to their much needed medications. We are also supporting various Governments in their efforts to combat Covid-19. In terms of business performance, we have done well and have started gaining market share in India. Our global specialty business has also gained reasonable traction with Ilumya recording approximately $94 million sales globally in the first full year of commercialization. Our endeavor will be to gain market share in each of our businesses by doing better, despite the near term uncertainties related to Covid-19.'

The company said that the Covid-19 pandemic has resulted in most countries imposing lockdowns on almost all economic activities. The pharmaceutical sector, being a supplier of essential items, has been relatively better-off compared to most other industries. However, the drug major estimates some softening of sales in the near term due to the lockdown and stocking up by customers, although it is difficult to quantify the impact as of now.

Sun Pharma is a specialty generic manufacturing pharmaceutical company.

The stock lost 1.85% to Rs 450.55 on Wednesday. During the day, the stock fell 3.47% to hit the day's low at Rs 443.10.

27-May-2020  Board of Sun Pharmaceuticals Industries recommends final divid...
Board of Sun Pharmaceuticals Industries recommends final dividend

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 27 May 2020, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 100%) , subject to the approval of the shareholders.
27-May-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on May 26, 2020. Total no. of equity shares bought back are 0
26-May-2020  Sun Pharmaceuticals Industries Ltd gains for fifth session
Sun Pharmaceuticals Industries Ltd gains for fifth session

Sun Pharmaceuticals Industries Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 471.35, up 0.42% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 9096.6. The Sensex is at 30896.17, up 0.73%. Sun Pharmaceuticals Industries Ltd has dropped around 3.79% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has dropped around 0.28% in last one month and is currently quoting at 9600.65, up 0.3% on the day. The volume in the stock stood at 49.87 lakh shares today, compared to the daily average of 113.83 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 469.7, up 0.12% on the day. Sun Pharmaceuticals Industries Ltd is up 13.62% in last one year as compared to a 23.72% fall in NIFTY and a 12.95% fall in the Nifty Pharma index.

The PE of the stock is 36.04 based on TTM earnings ending December 19.

26-May-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on May 22, 2020. Total no. of equity shares bought back are 0
23-May-2020  Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31...
Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 22, 2020 for Rakesh Sudhir Valia
22-May-2020  Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Indust...
Sun Pharmaceuticals Industries Ltd - Sun Pharmaceutical Industries Limited - Daily Buy-Back of equity shares

Sun Pharmaceutical Industries Limited has informed the Exchange regarding daily report pursuant to Regulation 15(i) of the Buyback Regulations regarding the equity shares bought-back on May 21, 2020. Total no. of equity shares bought back are 0
21-May-2020  Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31...
Sun Pharmaceuticals Industries Ltd - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 20, 2020 for Shanghvi Finance Pvt Ltd
Incorporation Year 1993 
Registered Office Sun Pharma Advanced Res.Centre,Tandalja,
Vadodara,
Gujarat-390020
Telephone 91-265-6615500 
Fax 91-265-2354897 
Chairman Israel Makov
Managing Director Dilip S Shanghvi
Company Secretary Sunil R Ajmera 
Auditor S R B C & Co LLP 
Face Value(Rs)
Market Lot
Listing BSE,MSEI,NSE 
Registrar Link Intime India Pvt Ltd
C-101 247 Park,L B S Marg,Vikhroli West,Mumbai-400083 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS